X

Trial Profile

68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gallium (68Ga) gozetotide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Diagnostic use

Most Recent Events

04 Jul 2022 Results from NCT02940262; NCT03353740, NCT03396874, retrospectively evaluating disease extent in men stratified by EAU BCR risk groups or biochemical persistence ,presented at the 37th Congress of the European Association of Urology
30 Jun 2021 Phase of the trial changed from Phase 2/3 to Phase 3.
30 Jun 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com